Grape King Bio Ltd
TWSE:1707
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (6.2), the stock would be worth NT$148.27 (26% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.9 | NT$117.5 |
0%
|
| 3-Year Average | 6.2 | NT$148.27 |
+26%
|
| 5-Year Average | 6.3 | NT$151.05 |
+29%
|
| Industry Average | 11 | NT$262.74 |
+124%
|
| Country Average | 14.6 | NT$347.73 |
+196%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
NT$13.9B
|
/ |
Jan 2026
NT$2.7B
|
= |
|
|
NT$13.9B
|
/ |
Dec 2026
NT$3.4B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
G
|
Grape King Bio Ltd
TWSE:1707
|
17.4B TWD | 4.9 | 14.3 | |
| FR |
|
L'Oreal SA
PAR:OR
|
184.4B EUR | 17.1 | 30.1 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
91.5B GBP | 11.2 | 11.1 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR | 36.8 | 38.2 | |
| UK |
|
HALEON PLC
LSE:HLN
|
30.8B GBP | 13 | 18.5 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
27.7B USD | 14.4 | -155.8 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
16.2B EUR | 8.1 | 17.3 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 10 | 22.6 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR | 38.5 | 63.9 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -6 373.4 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
815.9B INR | 32.3 | 44.3 |
Market Distribution
| Min | 0.8 |
| 30th Percentile | 10.5 |
| Median | 14.6 |
| 70th Percentile | 22.8 |
| Max | 2 788.3 |
Other Multiples
Grape King Bio Ltd
Glance View
Grape King Bio Ltd. engages in the production and sale of pharmaceutical preparations, patent medicine, liquid tonics, drinks, and healthy food. The company is headquartered in Taoyuan, Taoyuan. The firm operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The firm operates in Taiwan, mainland China and other markets.
